North Star Asset Management’s Pacira BioSciences PCRX Stock Holding History

North Star Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,400	Closed	-$239K	–	248
2016 Q4	$239K	Hold	7,400	–	–	0.03%	215
2016 Q3	$253K	Hold	7,400	–	–	0.03%	208
2016 Q2	$250K	Hold	7,400	–	–	0.03%	210
2016 Q1	$392K	Hold	7,400	–	–	0.05%	183
2015 Q4	$568K	Hold	7,400	–	–	0.07%	168
2015 Q3	$304K	Hold	7,400	–	–	0.04%	198
2015 Q2	$523K	Buy	7,400 +2,300	+45%	+$181K	0.06%	179
2015 Q1	$453K	Sell	5,100 -2,200	-30%	-$223K	0.05%	187
2014 Q4	$647K	Hold	7,300	–	–	0.07%	166
2014 Q3	$708K	Buy	7,300 +2,300	+46%	+$224K	0.08%	160
2014 Q2	$459K	Hold	5,000	–	–	0.05%	186
2014 Q1	$350K	Buy	+5,000	New	+$340K	0.04%	194

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

North Star Asset Management's PCRX Position: Q1 2017 in Review

North Star Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2017, closing a stake of 7,400 shares — an estimated $239K sold.

North Star Asset Management first reported a position in PCRX in Q1 2014 and held it in 12 quarters. The position peaked at $708K in Q3 2014. 192 funds tracked by Wall St. Rank hold PCRX as of Q1 2017.

North Star Asset Management reported no remaining Pacira BioSciences position as of Q1 2017 after selling out during the quarter.
North Star Asset Management sold 7,400 Pacira BioSciences shares in Q1 2017, an estimated $239K.
North Star Asset Management first reported a position in Pacira BioSciences in Q1 2014 and held it in 12 quarters.
North Star Asset Management's Pacira BioSciences position peaked at $708K in Q3 2014.
192 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2017.

Based on North Star Asset Management's 13F filing for Q1 2017, filed 18 May 2017.